Selection of patients for re-irradiation with local implants in carcinomas of oropharynx and tongue.
Between 1972 and 1984, 123 patients with recurrent or new primary carcinomas in previously irradiated areas of soft palate, tonsil, base of tongue or mobile tongue were re-irradiated with iridium-192 afterloading techniques. The average re-irradiation dose was 62 Gy (31-84 Gy) and the total dose 131 Gy (92-162 Gy); only 28 cases of mucosal necrosis were observed (23%). Two and 5 years actuarial local control rates were 67% and 59% and survival rates 48% and 24% respectively. Death was related to local tumor in 48 cases, metastases in 8 cases and intercurrent disease in 39 cases. We analyzed the effect on survival and local control of age, initial tumor site and volume, previous surgery, time between first irradiation and re-irradiation, doses, dose rate, and techniques of brachytherapy. With this analysis as background, we recommend the use of salvage brachytherapy for patients with a) small tumors of soft palate, tonsil or mobile tongue without synchronic lymph node metastases, b) long time interval between first irradiation and re-irradiation, c) new primary tumors (rather than recurrence of first tumor), and d) no previous local surgery. A high re-irradiation dose given with low dose rate is recommended.
Langlois
D
D
Department of Brachytherapy, Centre Alexis Vautrin, Vandoeuvre les Nancy, France.
Hoffstetter
S
S
Pernot
M
M
D000328:Adult; D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects; D006801:Humans; D007496:Iridium Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009959:Oropharyngeal Neoplasms / Q000532:radiotherapy*; D010610:Pharyngeal Neoplasms / Q000532:radiotherapy*; D014062:Tongue Neoplasms / Q000532:radiotherapy*
D007496:Iridium Radioisotopes